US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Actuate Therapeutics Inc

2.62

-0.2800-9.66%

Volume:85.70K

Turnover:233.68K

Market Cap:62.69M

PE:-2.68

High:2.96

Open:2.88

Low:2.61

Close:2.90

52wk High:11.99

52wk Low:1.58

Shares:23.93M

Float Shares:8.89M

Volume Ratio:0.42

T/O Rate:0.96%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9775

EPS(LYR):-1.0574

ROE:-553.75%

ROA:-203.78%

PB:16.56

PE(LYR):-2.48

Loading ...

Overview Company News Filings

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)

Actuate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Actuate Therapeutics Q1 net loss narrows 10.94% to $5.63 million

Actuate Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Analysts Are Bullish on These Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGIO)

Actuate Therapeutics receives FDA clearance for oral elraglusib study

Actuate Therapeutics adds Martin Huber to board of directors

Actuate Therapeutics wins FDA IND clearance for oral elraglusib cancer trial

Actuate Therapeutics Inc - FDA Clears Ind for Phase 1/2 Study of Oral Elraglusib in Advanced Cancer Patients

THOMSON REUTERS

Actuate Therapeutics Inc - Elraglusib Plus Ras Inhibitor Preclinical Results Expected in Mid-2026

THOMSON REUTERS

Actuate Therapeutics Announces FDA Clearance of Ind for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

THOMSON REUTERS

Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics director Martin H. Huber Jr files initial beneficial ownership statement

Actuate Therapeutics Adds Oncology Expert to Board Leadership

Actuate Therapeutics names Martin Huber to board as independent director

Press Release: Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial

Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?

B. Riley Cuts Actuate Therapeutics Price Target to $8 From $20, Maintains Buy Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACTU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":2.62,"timestamp":1778875200000,"preClose":2.9,"halted":0,"volume":85696,"delay":0,"changeRate":-0.09655172413793096,"floatShares":8886400,"shares":23925852,"eps":-0.977528,"marketStatus":"Pre-Mkt","change":-0.28,"latestTime":"05-18 07:01:48 EDT","open":2.88,"high":2.955,"low":2.61,"amount":233680.53180159998,"amplitude":0.118966,"askPrice":4.19,"askSize":200,"bidPrice":2.47,"bidSize":142,"shortable":0,"etf":0,"ttmEps":-0.977528,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":2.62,"postHourTrading":{"tag":"盘后","latestPrice":2.62,"preClose":2.62,"latestTime":"19:43 EDT","volume":513,"amount":1344.06,"timestamp":1778888608960,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4235881545215111},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":8886400,"roa":"-203.78%","roe":"-553.75%","lyrEps":-1.05737,"volumeRatio":0.4235881545215111,"shares":23925852,"dividePrice":0,"high":2.955,"amplitude":0.118966,"preClose":2.9,"low":2.61,"week52Low":1.58,"pbRate":"16.56","week52High":11.99,"institutionHeld":0,"latestPrice":2.62,"committee":-0.169591,"eps":-0.977528,"divideRate":0,"volume":85696,"delay":0,"ttmEps":-0.977528,"open":2.88,"prevYearClose":6.12,"prevWeekClose":2.62,"prevMonthClose":2.94,"prevQuarterClose":2.74,"fiveDayClose":3.3,"twentyDayClose":2.31,"sixtyDayClose":4.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-14","symbol":"ACTU","fiscalQuarterEnding":"2026/03","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2026-03-26","symbol":"ACTU","fiscalQuarterEnding":"2025/12","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2025-11-13","symbol":"ACTU","fiscalQuarterEnding":"2025/09","expectedEps":-0.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-08-14","symbol":"ACTU","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.3},{"market":"US","date":"2025-05-15","symbol":"ACTU","fiscalQuarterEnding":"2025/03","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1756180800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2026-05-15","current":-2.68023,"percent":0.892377,"low":-9.225925,"twenty":-6.536778,"median":-5.667354,"eighty":-4.71569,"high":-1.834819,"avg":-5.491935,"sd":1.356987,"marketCap":69384970},"quantilePoints":[{"date":"2024-07-25","current":-6.211408,"twenty":-6.211408,"median":-6.211408,"eighty":-6.211408,"marketCap":172493433},{"date":"2024-08-09","current":-5.505609,"twenty":-6.211408,"median":-6.211408,"eighty":-6.070248,"marketCap":152893088},{"date":"2024-08-16","current":-5.987349,"twenty":-6.211408,"median":-6.167236,"eighty":-5.841451,"marketCap":166271233},{"date":"2024-08-23","current":-5.560665,"twenty":-6.211408,"median":-5.987349,"eighty":-5.556536,"marketCap":154422018},{"date":"2024-08-30","current":-5.540019,"twenty":-6.211408,"median":-5.870355,"eighty":-5.533137,"marketCap":153848669},{"date":"2024-09-06","current":-5.608839,"twenty":-6.158401,"median":-5.624324,"eighty":-5.529008,"marketCap":155759833},{"date":"2024-09-13","current":-5.512491,"twenty":-6.078798,"median":-5.608839,"eighty":-5.512491,"marketCap":153084204},{"date":"2024-09-20","current":-5.03075,"twenty":-6.012125,"median":-5.608839,"eighty":-5.509738,"marketCap":139706059},{"date":"2024-09-27","current":-4.249491,"twenty":-5.950186,"median":-5.560665,"eighty":-5.486339,"marketCap":122463357},{"date":"2024-10-04","current":-5.056014,"twenty":-5.921282,"median":-5.540019,"eighty":-5.041842,"marketCap":145706004},{"date":"2024-10-11","current":-4.981461,"twenty":-5.86072,"median":-5.519373,"eighty":-4.824223,"marketCap":143557524},{"date":"2024-10-18","current":-4.920464,"twenty":-5.785018,"median":-5.512491,"eighty":-4.844556,"marketCap":141799677},{"date":"2024-10-25","current":-5.774428,"twenty":-5.765917,"median":-5.512491,"eighty":-4.844556,"marketCap":166409538},{"date":"2024-11-01","current":-5.306781,"twenty":-5.809795,"median":-5.512491,"eighty":-4.893354,"marketCap":152932709},{"date":"2024-11-08","current":-5.937088,"twenty":-5.927371,"median":-5.540019,"eighty":-4.957062,"marketCap":171097131},{"date":"2024-11-15","current":-5.958745,"twenty":-5.939799,"median":-5.550342,"eighty":-5.011034,"marketCap":169534600},{"date":"2024-11-22","current":-6.164693,"twenty":-5.973458,"median":-5.595075,"eighty":-5.037775,"marketCap":175394091},{"date":"2024-11-29","current":-5.581175,"twenty":-6.024512,"median":-5.608839,"eighty":-5.04517,"marketCap":158792200},{"date":"2024-12-06","current":-6.144098,"twenty":-6.055165,"median":-5.638088,"eighty":-5.051947,"marketCap":174808142},{"date":"2024-12-13","current":-5.917556,"twenty":-6.037784,"median":-5.643249,"eighty":-5.107523,"marketCap":168362702},{"date":"2024-12-20","current":-4.647547,"twenty":-6.017783,"median":-5.638088,"eighty":-5.04517,"marketCap":132229175},{"date":"2024-12-27","current":-6.068584,"twenty":-6.019156,"median":-5.638088,"eighty":-5.043814,"marketCap":172659662},{"date":"2025-01-03","current":-5.718473,"twenty":-6.013664,"median":-5.622603,"eighty":-5.049236,"marketCap":162698527},{"date":"2025-01-10","current":-5.697878,"twenty":-5.992612,"median":-5.622603,"eighty":-5.054658,"marketCap":162112578},{"date":"2025-01-17","current":-5.917556,"twenty":-5.969958,"median":-5.636367,"eighty":-5.146627,"marketCap":168362702},{"date":"2025-01-24","current":-6.940428,"twenty":-6.032033,"median":-5.643249,"eighty":-5.178584,"marketCap":197464839},{"date":"2025-01-31","current":-6.199017,"twenty":-6.064465,"median":-5.677284,"eighty":-5.209185,"marketCap":176370673},{"date":"2025-02-07","current":-6.047989,"twenty":-6.091559,"median":-5.691423,"eighty":-5.241176,"marketCap":172073713},{"date":"2025-02-14","current":-5.327173,"twenty":-6.072917,"median":-5.687582,"eighty":-5.255778,"marketCap":151565495},{"date":"2025-02-21","current":-5.279119,"twenty":-6.065838,"median":-5.658037,"eighty":-5.254405,"marketCap":150198280},{"date":"2025-02-28","current":-4.970198,"twenty":-6.060665,"median":-5.639808,"eighty":-5.174772,"marketCap":141409044},{"date":"2025-03-07","current":-4.771115,"twenty":-6.057666,"median":-5.608839,"eighty":-5.040292,"marketCap":135744870},{"date":"2025-03-14","current":-5.189762,"twenty":-6.053039,"median":-5.581175,"eighty":-5.033989,"marketCap":141604361},{"date":"2025-03-21","current":-4.831847,"twenty":-6.048768,"median":-5.560665,"eighty":-5.014488,"marketCap":131838543},{"date":"2025-03-28","current":-5.655051,"twenty":-6.042497,"median":-5.560665,"eighty":-5.033989,"marketCap":154299924},{"date":"2025-04-04","current":-4.932064,"twenty":-6.028767,"median":-5.540019,"eighty":-4.987939,"marketCap":134572972},{"date":"2025-04-11","current":-5.483252,"twenty":-6.017783,"median":-5.519391,"eighty":-4.984609,"marketCap":149612331},{"date":"2025-04-17","current":-5.726634,"twenty":-6.012291,"median":-5.540019,"eighty":-4.990995,"marketCap":156253088},{"date":"2025-04-25","current":-6.406672,"twenty":-6.045243,"median":-5.553757,"eighty":-4.998855,"marketCap":174808142},{"date":"2025-05-02","current":-7.537682,"twenty":-6.061192,"median":-5.567445,"eighty":-5.009067,"marketCap":205668127},{"date":"2025-05-09","current":-7.408833,"twenty":-6.107591,"median":-5.601957,"eighty":-5.032369,"marketCap":202152432},{"date":"2025-05-16","current":-8.179286,"twenty":-6.139979,"median":-5.636367,"eighty":-5.039569,"marketCap":206987413},{"date":"2025-05-23","current":-7.830407,"twenty":-6.178422,"median":-5.644452,"eighty":-5.043814,"marketCap":198158566},{"date":"2025-05-30","current":-8.194792,"twenty":-6.211408,"median":-5.662735,"eighty":-5.049236,"marketCap":207379806},{"date":"2025-06-06","current":-7.047366,"twenty":-6.281396,"median":-5.690843,"eighty":-5.056014,"marketCap":178342709},{"date":"2025-06-13","current":-6.675228,"twenty":-6.406672,"median":-5.69465,"eighty":-5.089546,"marketCap":168925272},{"date":"2025-06-20","current":-5.806906,"twenty":-6.42894,"median":-5.722554,"eighty":-5.141086,"marketCap":146951253},{"date":"2025-06-27","current":-4.512175,"twenty":-6.410449,"median":-5.697878,"eighty":-5.08284,"marketCap":114186421},{"date":"2025-07-03","current":-5.109147,"twenty":-6.389172,"median":-5.691014,"eighty":-5.046525,"marketCap":129293559},{"date":"2025-07-11","current":-4.791279,"twenty":-6.365148,"median":-5.677284,"eighty":-5.035608,"marketCap":121249498},{"date":"2025-07-18","current":-4.853302,"twenty":-6.320988,"median":-5.645656,"eighty":-4.991444,"marketCap":122819071},{"date":"2025-07-25","current":-5.419262,"twenty":-6.287654,"median":-5.638088,"eighty":-4.976956,"marketCap":137141423},{"date":"2025-08-01","current":-5.620836,"twenty":-6.265937,"median":-5.628589,"eighty":-4.986182,"marketCap":142242535},{"date":"2025-08-08","current":-6.527901,"twenty":-6.287654,"median":-5.632466,"eighty":-4.991444,"marketCap":165196967},{"date":"2025-08-15","current":-6.908485,"twenty":-6.414227,"median":-5.639808,"eighty":-4.995735,"marketCap":170525437},{"date":"2025-08-22","current":-6.442036,"twenty":-6.458702,"median":-5.650353,"eighty":-5.00125,"marketCap":159011858},{"date":"2025-08-29","current":-6.908485,"twenty":-6.483225,"median":-5.670419,"eighty":-5.019908,"marketCap":170525437},{"date":"2025-09-05","current":-7.328709,"twenty":-6.512404,"median":-5.690843,"eighty":-5.033989,"marketCap":180898030},{"date":"2025-09-12","current":-5.859066,"twenty":-6.574176,"median":-5.69465,"eighty":-5.040292,"marketCap":144622132},{"date":"2025-09-19","current":-6.375067,"twenty":-6.549229,"median":-5.726634,"eighty":-5.04517,"marketCap":157358843},{"date":"2025-09-26","current":-6.175411,"twenty":-6.549229,"median":-5.729418,"eighty":-5.051947,"marketCap":152430635},{"date":"2025-10-03","current":-6.212557,"twenty":-6.533707,"median":-5.754096,"eighty":-5.069427,"marketCap":153347511},{"date":"2025-10-10","current":-7.512643,"twenty":-6.537578,"median":-5.770478,"eighty":-5.097386,"marketCap":185438171},{"date":"2025-10-17","current":-7.24334,"twenty":-6.589924,"median":-5.79172,"eighty":-5.109147,"marketCap":178790820},{"date":"2025-10-24","current":-6.732591,"twenty":-6.670885,"median":-5.814177,"eighty":-5.112248,"marketCap":166183775},{"date":"2025-10-31","current":-6.110407,"twenty":-6.6744,"median":-5.859066,"eighty":-5.12,"marketCap":150826102},{"date":"2025-11-07","current":-5.785385,"twenty":-6.670885,"median":-5.869501,"eighty":-5.13638,"marketCap":142803437},{"date":"2025-11-14","current":-5.536933,"twenty":-6.66337,"median":-5.85039,"eighty":-5.154603,"marketCap":136670768},{"date":"2025-11-21","current":-5.868654,"twenty":-6.637844,"median":-5.836285,"eighty":-5.160645,"marketCap":141551867},{"date":"2025-11-28","current":-7.352682,"twenty":-6.647528,"median":-5.86386,"eighty":-5.168486,"marketCap":177346592},{"date":"2025-12-05","current":-7.082858,"twenty":-6.676544,"median":-5.869501,"eighty":-5.172026,"marketCap":170838460},{"date":"2025-12-12","current":-7.150314,"twenty":-6.706669,"median":-5.884194,"eighty":-5.183365,"marketCap":172465493},{"date":"2025-12-19","current":-6.764853,"twenty":-6.718803,"median":-5.896423,"eighty":-5.185781,"marketCap":163168162},{"date":"2025-12-26","current":-6.321572,"twenty":-6.721745,"median":-5.917556,"eighty":-5.189762,"marketCap":152476231},{"date":"2026-01-02","current":-5.897564,"twenty":-6.709975,"median":-5.917556,"eighty":-5.218313,"marketCap":142249167},{"date":"2026-01-09","current":-6.051748,"twenty":-6.706828,"median":-5.918043,"eighty":-5.231645,"marketCap":145968099},{"date":"2026-01-16","current":-5.12664,"twenty":-6.706347,"median":-5.916837,"eighty":-5.218313,"marketCap":123654504},{"date":"2026-01-23","current":-5.251915,"twenty":-6.701519,"median":-5.896423,"eighty":-5.230096,"marketCap":126676137},{"date":"2026-01-30","current":-4.567721,"twenty":-6.691045,"median":-5.884194,"eighty":-5.187481,"marketCap":110173374},{"date":"2026-02-06","current":-4.162986,"twenty":-6.680588,"median":-5.869501,"eighty":-5.163192,"marketCap":100411176},{"date":"2026-02-13","current":-4.085894,"twenty":-6.675886,"median":-5.86386,"eighty":-5.121593,"marketCap":98551710},{"date":"2026-02-20","current":-4.085894,"twenty":-6.6744,"median":-5.836285,"eighty":-5.109147,"marketCap":98551710},{"date":"2026-02-27","current":-3.806434,"twenty":-6.670885,"median":-5.810835,"eighty":-5.051947,"marketCap":91811145},{"date":"2026-03-06","current":-3.083693,"twenty":-6.66337,"median":-5.801368,"eighty":-5.014488,"marketCap":74378649},{"date":"2026-03-13","current":-2.457318,"twenty":-6.638594,"median":-5.7914,"eighty":-4.984609,"marketCap":59270486},{"date":"2026-03-20","current":-2.409136,"twenty":-6.610668,"median":-5.770478,"eighty":-4.925104,"marketCap":58108320},{"date":"2026-03-27","current":-2.421357,"twenty":-6.609918,"median":-5.754096,"eighty":-4.858871,"marketCap":53821570},{"date":"2026-04-02","current":-2.656026,"twenty":-6.605591,"median":-5.74824,"eighty":-4.848283,"marketCap":59037758},{"date":"2026-04-10","current":-2.016167,"twenty":-6.591355,"median":-5.726634,"eighty":-4.839764,"marketCap":44815069},{"date":"2026-04-17","current":-2.293524,"twenty":-6.585305,"median":-5.718473,"eighty":-4.830404,"marketCap":50980105},{"date":"2026-04-24","current":-2.698891,"twenty":-6.578607,"median":-5.699843,"eighty":-4.807832,"marketCap":59990542},{"date":"2026-05-01","current":-3.13626,"twenty":-6.553112,"median":-5.691423,"eighty":-4.789745,"marketCap":69712330},{"date":"2026-05-08","current":-3.562962,"twenty":-6.537578,"median":-5.687496,"eighty":-4.757961,"marketCap":79197001},{"date":"2026-05-15","current":-3.221727,"twenty":-6.536778,"median":-5.667354,"eighty":-4.71569,"marketCap":69384970}],"updateTime":1779079233062},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636247180","title":"Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636247180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636247180?lang=en_us&edition=fundamental","pubTime":"2026-05-18 18:20","pubTimestamp":1779099611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-and-actuate-therapeutics-inc-actu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-and-actuate-therapeutics-inc-actu-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XLV","BK4139","LU0029874061.USD","BK4581","BK4585","BK4137","PYXS","HCSG","BK4588","LU0128526141.USD","XBI","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635581830","title":"Actuate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635581830","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635581830?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:01","pubTimestamp":1778878868,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryActuate Therapeutics Inc ACTU.OQ reported a quarterly adjusted loss of 24 cents per share for the quarter ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S25P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710728","title":"Actuate Therapeutics Q1 net loss narrows 10.94% to $5.63 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710728","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710728?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:02","pubTimestamp":1778788969,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics posted a net loss of $5.63 million for the quarter ended March 31, 2026, narrowing from $6.32 million a year earlier.Operating loss improved to $5.71 million as total operating expenses fell to $5.71 million from $6.37 million.Research and development expense dropped to $2.57 million from $3.22 million, due to lower external clinical study costs and lower CMC spending.Pipeline update: FDA cleared a Phase 1/2 study for the oral elraglusib tablet following an IND filing in April 2026, while updated Phase 2 mPDAC data presented in January 2026 showed median overall survival of 10.1 months with elraglusib plus GnP versus 7.2 months for GnP alone.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL7vnH4n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758989","title":"Actuate Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758989","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758989?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:03","pubTimestamp":1778702585,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc  expected to post a loss of22cents a share - Earnings Preview Actuate Therapeutics Inc ACTU.OQ ACTU.O is expected to  show no change in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278805","title":"Analysts Are Bullish on These Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278805","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635278805?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:20","pubTimestamp":1778667636,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGI...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-actuate-therapeutics-inc-actu-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-actuate-therapeutics-inc-actu-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","LABU","BK4112","BK4581","LU0128526141.USD","BK4139","BK4585","XBI","BK4588","AGIO","LU0029874061.USD","BLSG","BK4137","BLSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634287109","title":"Actuate Therapeutics receives FDA clearance for oral elraglusib study","url":"https://stock-news.laohu8.com/highlight/detail?id=2634287109","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634287109?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:55","pubTimestamp":1778507748,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) announced the FDA has cleared its investigational new drug application to conduct a Phase 1/2 study of oral elraglusib ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-receives-fda-clearance-for-oral-elraglusib-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/actuate-therapeutics-receives-fda-clearance-for-oral-elraglusib-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4588","ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634283487","title":"Actuate Therapeutics adds Martin Huber to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634283487","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634283487?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:16","pubTimestamp":1778498173,"startTime":"0","endTime":"0","summary":"Huber is a board member at Syndax Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL275FtH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634880962","title":"Actuate Therapeutics wins FDA IND clearance for oral elraglusib cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634880962","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634880962?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:04","pubTimestamp":1778497477,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics received FDA clearance of an IND for oral elraglusib.Phase 1/2 trial in advanced solid tumors planned to start in 2H 2026, targeting higher drug exposure than IV formulation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8sjZ8f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","ACTU","BK4139","BK4588","LU2210150020.SGD","LU2210149790.SGD","SG9999014021.USD","BK4112","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288486","title":"Actuate Therapeutics Inc - FDA Clears Ind for Phase 1/2 Study of Oral Elraglusib in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634288486?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUAFKBM0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288454","title":"Actuate Therapeutics Inc - Elraglusib Plus Ras Inhibitor Preclinical Results Expected in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634288454?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUAFKBM0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288195","title":"Actuate Therapeutics Announces FDA Clearance of Ind for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288195","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634288195?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUAFKBM0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634828842","title":"Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634828842","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634828842?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497200,"startTime":"0","endTime":"0","summary":"-- Elraglusib oral tablet formulation to drive next-phase clinical. -- FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer. patients, with focus on metastatic melanoma, NSCLC, colorectal, and. pancreatic cancers with initiation planned for 2H 2026. To support this initiative, the Company recently received Investigational New Drug  clearance from FDA to conduct a Phase 1/2 study designed to demonstrate that a higher overall exposure to elraglusib can be achieved with the oral formulation compared to the IV formulation. The study will evaluate the safety and potential efficacy of the oral formulation as a monotherapy in solid tumor patients, including those with metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, based on evidence of efficacy of the IV formulation in prior clinical studies and machine learning therapeutic target analyses.\"Advancing the elraglusib oral tablet is an important element to the success of our overall development strategy,\" sai","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4081","LU2413666426.HKD","LU2211817866.USD","IE00BYQQ9H92.USD","LU1721428933.USD","BK4121","LU1093756325.SGD","BK4585","ACTU","BK4588","IND","IE00BFXG0V08.USD","BK4181","BK4548","BK4218","LU0347712357.USD","BK4567","IE00B5TLWC47.USD","MTD","BK4533","LABU","EMA","LU1093756168.USD","BK4139","LU2413666699.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633415935","title":"Actuate Therapeutics director Martin H. Huber Jr files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2633415935","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633415935?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:00","pubTimestamp":1778097653,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics disclosed director Martin H. Huber Jr. received 30,000 non-qualified stock options exercisable at USD 3, expiring May 1, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL3R6ZVy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633935134","title":"Actuate Therapeutics Adds Oncology Expert to Board Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2633935134","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633935134?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:21","pubTimestamp":1778077276,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics, Inc. ( ($ACTU) ) just unveiled an update. On May 1, 2026, Actuate Therapeutics, Inc. expanded its Board of Directors from sev...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-adds-oncology-expert-to-board-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-adds-oncology-expert-to-board-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633355341","title":"Actuate Therapeutics names Martin Huber to board as independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2633355341","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633355341?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:45","pubTimestamp":1778071514,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics appointed Martin Huber, MD, as independent director, effective immediately.Huber most recently served as president and CEO of Mersana Therapeutics until its acquisition by Day One Pharmaceuticals in January 2026.He previously held senior R&D leadership roles at Xilio Therapeutics, TESARO, including chief medical officer.Board addition comes as company advances elraglusib across multiple cancer indications toward registration studies, commercialization.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL3DJdXs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","IE00B3T34201.USD","LU0575583348.USD","LU1046248800.SGD","LU1064927863.SGD","LU1400636657.SGD","NDAQ","LU1309081286.SGD","SGXZ57979304.SGD","LU0109981661.USD","SG9999014005.SGD","LU2468319806.SGD","LU1481600234.SGD","LU1035777561.USD","BK4585","LU1228905037.USD","LU2646069778.SGD","LU1302929846.USD","LU1645745479.HKD","LU0161305163.EUR","IE00BKPKM429.USD","LU1098665638.USD","LU2095319765.USD","IE00B64PRP62.GBP","LU0203345920.USD","GSK.UK","LU0203347892.USD","LU0321505439.SGD","IE0034235071.USD","BK4588","LU0971552673.USD","SG9999014039.USD","LU0225283273.USD","LU0306806265.USD","SG9999014013.SGD","LU2089984988.USD","LU0545562505.USD","LU0557290698.USD","LU0987226296.USD","SG9999013999.USD","LU0225771236.USD","IE00BQJZX424.USD","LU0971552830.HKD","ACTU","LU1983299246.USD","LU2210150020.SGD","LU1202635105.USD","IE00BN0W2W23.USD","IE00BWDBJ516.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633355691","title":"Press Release: Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2633355691","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633355691?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:45","pubTimestamp":1778071500,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, May 06, 2026  -- Actuate Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced the appointment of Martin Huber, MD, as an Independent Director, effective immediately. This appointment strengthens Actuate's leadership team as it advances elraglusib across multiple difficult-to-treat cancer indications toward registration studies and commercialization.Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational drug, elraglusib , targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells  and DNA Damage Response . Elraglusib may also mediate anti-tum","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629649046","title":"Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2629649046","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629649046?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:09","pubTimestamp":1776859740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACTU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 08:09 ET (12:09 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629050857","title":"Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629050857","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629050857?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:12","pubTimestamp":1776802353,"startTime":"0","endTime":"0","summary":"Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trialHealth Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidApril 21  - Hello Health Rounds readers!","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nL1N4140ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627267167","title":"Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?","url":"https://stock-news.laohu8.com/highlight/detail?id=2627267167","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627267167?lang=en_us&edition=fundamental","pubTime":"2026-04-16 15:34","pubTimestamp":1776324840,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data showing elraglusib plus chemotherapy improved overall survival in metastatic pancreatic cancer.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/16/Telemedicine-And-Human-Pancreas-Recovery.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/16/Telemedicine-And-Human-Pancreas-Recovery.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/equities/26/04/51850128/why-did-actuate-therapeutics-actu-stock-jump-over-14-after-hours","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/04/51850128/why-did-actuate-therapeutics-actu-stock-jump-over-14-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["ACTU","BK4139","RSI","BK4150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627280850","title":"B. Riley Cuts Actuate Therapeutics Price Target to $8 From $20, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2627280850","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627280850?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:27","pubTimestamp":1776259674,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (ACTU) has an average rating of Buy and mean price target of $16.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACTU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}